Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.42 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913932 | 1.00 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1BTK | |
| Hydrochloric Acid SCHEMBL14990786 | 0.99 | PDE5A (0.45) | PDE5AGUCY1A1GUCY1B1BTK | |
| Formic Acid SCHEMBL30884591 | 0.95 | PDE5A (0.45) | PDE5AGUCY1A1GUCY1B1 | |
| Acetic Acid SCHEMBL428284 | 0.94 | PDE5A (0.48) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL9913943 | 0.91 | PDE5A (0.41) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20433877 | 0.89 | ADORA3 (0.39) | PDE5AGUCY1A1GUCY1B1BTK | |
| SCHEMBL9913976 | 0.88 | PDE5A (0.39) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174635 | 0.88 | PDE5A (0.48) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL326267 | 0.88 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL29219152 | 0.87 | PDE5A (0.47) | PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276969-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | MOEHS IBERICA, S.L. (ES) | 2025-09-04 | — | — | US | claimed |
| US-20250276969-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | MOEHS IBERICA, S.L. (ES) | 2025-09-04 | — | — | US | disclosed |
| EP-4519262-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | Moehs Ibérica, S.L. (ES) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213525-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | MOEHS IBERICA, S.L. (ES) | 2023-11-09 | — | — | WO | disclosed |
| CN-108690016-B | Pyrazolopyridines and uses thereof | 广东东阳光药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276969-A1 | 2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT | DPYD, AGT, DNTT | PDE5A 1299/4885GUCY1A1 1117/4885GUCY1B1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.